Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

686
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

161
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
161

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of BMI and OGTT glucose measures with pregnancy outcomes in risk-based screening for GDM.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2026
Same author

Physiologically-based pharmacokinetic modelling of uridine 5'-diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women.

British journal of clinical pharmacology·2026
Same author

Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester.

European journal of clinical pharmacology·2026
Same author

Generation and viability evaluation of human precision-cut placental slices for ex vivo studies.

Placenta·2026
Same author

Preferences regarding preconceptional and genetic counselling and pregnancy check-ups among women with the PLN p. (Arg14del) variant.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2026
Same author

Outcomes and management strategies of pregnancies after heart and lung transplantation across Europe.

JHLT open·2026

Related Experiment Video

Updated: Apr 25, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

3.2K

Immunomodulators to treat recurrent miscarriage.

Jelmer R Prins1, Tom E C Kieffer1, Sicco A Scherjon1

  • 1Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, PO Box 30001, Hanzeplein 1, 9700 RB Groningen, The Netherlands.

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|August 27, 2014
PubMed
Summary

Recurrent miscarriage, often unexplained, may stem from maternal immune system maladaptation. Immune modulation shows promise for improving pregnancy outcomes, but more research is needed on safety and efficacy.

Keywords:
Immune systemRecurrent miscarriageReviewTherapy

More Related Videos

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.9K
Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy
08:29

Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy

Published on: October 25, 2024

1.9K

Related Experiment Videos

Last Updated: Apr 25, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

3.2K
Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

1.9K
Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy
08:29

Author Spotlight: Multiplex Immunohistochemistry for Understanding Immune Regulation by Uterine NK Cells in Pregnancy

Published on: October 25, 2024

1.9K

Area of Science:

  • Reproductive immunology
  • Immunology
  • Obstetrics

Background:

  • Recurrent miscarriage (RM) affects many couples, with over 50% of cases having unknown etiology.
  • Maternal immune system maladaptation is a potential contributor to RM pathophysiology.
  • Current understanding of RM causes necessitates further investigation into immune system involvement.

Discussion:

  • Modulating the maternal immune system towards pregnancy tolerance offers a potential therapeutic strategy for RM.
  • Immune modulators, particularly those promoting a regulatory T cell-rich environment, show promise.
  • Existing studies on immune modulators for RM are limited, highlighting a need for more research.

Key Insights:

  • Immune system maladaptation is a significant factor in recurrent miscarriage.
  • Targeting immune tolerance could improve pregnancy outcomes in RM.
  • Therapeutic strategies require further validation and safety assessments.

Outlook:

  • Further research is crucial to identify safe and effective maternal immune modulators for RM.
  • Elucidating potential side effects on maternal, fetal, and neonatal immunity is essential.
  • Clinical implementation of immune-modulating therapies for RM requires comprehensive safety and efficacy data.